A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. In order to participate in this study the following conditions must be met:
    2. have a life expectancy of at least 3 months
    3. have histologically or cytologically confirmed Stage 4 NSCLC (squamous or nonsquamous) and be considered for standard therapy with pembrolizumab and chemotherapy
    4. have not received prior systemic treatment for advanced/metastatic NSCLC

You may not be eligible for this study if the following are true:

    1. You will not be able to participate in this study if you have:
    2. does not have predominantly squamous cell or nonsquamous cell histology NSCLC
    3. is currently participating in or has participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001
    4. prior to the first dose of EIK1001, has received prior systemic therapy for metastatic disease



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.